Recombinetics

Executive Summary

Recombinetics is a leader in animal gene editing, developing custom gene-edited swine models for biomedical research and precision breeding for agriculture. Founded in 2008, the company leverages its expertise in synthetic biology and CRISPR to create porcine models that better mimic human diseases, enabling more predictive preclinical studies. In agriculture, its precision breeding aims to improve livestock traits such as disease resistance, growth efficiency, and sustainability. Despite being in a preclinical stage, Recombinetics has established a strong technological foundation and partnerships with research institutions. The company's dual focus on biomedicine and agriculture positions it for growth as regulatory frameworks for gene-edited animals evolve. However, its private status and early-stage development imply significant execution risks. The conviction score of 60 reflects the promising technology balanced by limited public milestones and a lengthy path to commercialization.

Upcoming Catalysts (preview)

• Q2 2026Partnership with a major pharmaceutical company for disease models70% success
• H2 2026FDA acceptance of gene-edited swine model for a specific therapeutic area50% success
• Q3 2026Published peer-reviewed validation of agricultural trait improvement in livestock80% success